These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23895653)

  • 21. A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma.
    Gustavsson A; Osterman B; Cavallin-Ståhl E
    Acta Oncol; 2003; 42(5-6):605-19. PubMed ID: 14596518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiation treatment for chemotherapy-resistant non-Hodgkin's lymphoma in the left thigh.
    Balasundaram S; Ramadas R; Stumpf J; Thirumalairaj R; Perumal K
    J Cancer Res Ther; 2017; 13(3):589-592. PubMed ID: 28862233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy.
    Myasoedova VA; Sukhorukov V; Grechko AV; Zhang D; Romanenko E; Orekhov V; Orekhov AN
    Curr Pharm Des; 2019; 25(6):635-641. PubMed ID: 30950345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Epigenetic abnormalities in non-Hodgkin lymphomas].
    Furukawa Y
    Rinsho Ketsueki; 2021; 62(9):1367-1381. PubMed ID: 34615796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical advances in epigenetic therapies for lymphoma.
    Rosenthal AC; Munoz JL; Villasboas JC
    Clin Epigenetics; 2023 Mar; 15(1):39. PubMed ID: 36871057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of rational and individualized therapeutic strategies for non-Hodgkin's lymphomas.
    Armitage JO
    Clin Lymphoma; 2002 Dec; 3 Suppl 1():S5-11. PubMed ID: 12521383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
    Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel therapeutics for aggressive non-Hodgkin's lymphoma.
    Mahadevan D; Fisher RI
    J Clin Oncol; 2011 May; 29(14):1876-84. PubMed ID: 21483007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Classification of non-Hodgkin's lymphomas in children.
    Perkins SL; Segal GH; Kjeldsberg CR
    Semin Diagn Pathol; 1995 Nov; 12(4):303-13. PubMed ID: 8578025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors.
    Katarzyna R; Lucyna B
    J Cancer Res Ther; 2019; 15(5):961-970. PubMed ID: 31603095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
    Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
    Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New therapeutic targets and drugs in non-Hodgkin's lymphoma.
    Sawas A; Diefenbach C; O'Connor OA
    Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
    Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
    J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
    Mazzone R; Zwergel C; Mai A; Valente S
    Clin Epigenetics; 2017; 9():59. PubMed ID: 28572863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.
    Maharaj L; Marson CM; Middleton BJ; Rioja AS; Perry J; Oakervee H; Cavenagh J; Joel SP; Popat R
    Br J Haematol; 2013 Oct; 163(1):135-9. PubMed ID: 23834265
    [No Abstract]   [Full Text] [Related]  

  • 36. Epigenetic therapy for solid tumors: from bench science to clinical trials.
    Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
    Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of non-Hodgkin's lymphomas.
    Mounter PJ; Lennard AL
    Postgrad Med J; 1999 Jan; 75(879):2-6. PubMed ID: 10396578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Romidepsin for the treatment of non-Hodgkin's lymphoma.
    Yazbeck VY; Grant S
    Expert Opin Investig Drugs; 2015; 24(7):965-79. PubMed ID: 25936363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds.
    Cox MC; Bocci G
    Cancer Lett; 2022 Jan; 524():144-150. PubMed ID: 34673128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment advances in non-Hodgkin's lymphoma.
    Tan BR; Bartlett NL
    Expert Opin Pharmacother; 2000 Mar; 1(3):451-66. PubMed ID: 11249530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.